Vertex Pharmaceuticals, Inc’s recently made public that its EVP, Chief Reg. & Quality Off. Tatsis Ourania unloaded Company’s shares for reported $2.14 million on Jan 07 ’26. In the deal valued at $474.99 per share,4,500 shares were sold. As a result of this transaction, Tatsis Ourania now holds 42,293 shares worth roughly $19.62 million.
Then, WAGNER CHARLES F JR sold 9,532 shares, generating $4,394,252 in total proceeds. Upon selling the shares at $461.00, the EVP, CO & FO now owns 37,725 shares.
Before that, Tatsis Ourania bought 4,500 shares. Vertex Pharmaceuticals, Inc shares valued at $2,137,455 were divested by the Officer at a price of $474.99 per share.
A number of analysts have revised their coverage, including Wolfe Research’s analysts, who increased its forecast for the stock in early January from “a Peer perform” to “an Outperform”. Morgan Stanley also remained covering VRTX and has increased its forecast on December 03, 2025 with a “an Overweight” recommendation from previously “an Equal-weight” rating. Scotiabank started covering the stock on November 13, 2025. It rated VRTX as “a Sector outperform”.
Price Performance Review of VRTX
On Monday, Vertex Pharmaceuticals, Inc [NASDAQ:VRTX] saw its stock fall -1.24% to $463.86. Over the last five days, the stock has gained 2.59%. Vertex Pharmaceuticals, Inc shares have risen nearly 13.60% since the year began. Nevertheless, the stocks have risen 2.32% over the past one year.
How much short interest is there in Vertex Pharmaceuticals, Inc?
A steep rise in short interest was recorded in Vertex Pharmaceuticals, Inc stocks on 2025-12-15, growing by 0.28 million shares to a total of 4.29 million shares. Yahoo Finance data shows the prior-month short interest on 2025-11-14 was 4.01 million shares. There was a rise of 6.55%, which implies that there is a positive sentiment for the stock.
